Sagimet's Denifanstat Hits 57% Acne Success at 52 Weeks

Sagimet Biosciences said on 30 September 2026 that its license partner Ascletis BioScience reported positive 52-week results from the Phase 3 ASC40-304 open-label extension of denifanstat in moderate to severe acne vulgaris, presented at the EADV Congress in Vienna. Treatment success reached 57.8% in patients who received denifanstat for the full 52 weeks and 55.6% in those who crossed over from placebo, a pooled 56.7%. Total lesion counts fell 71.8% and inflammatory lesions fell 76.9% versus the original trial baseline.

Context — why this matters now

Denifanstat is a once-daily oral fatty acid synthase inhibitor. Ascletis develops it as ASC40 in China under an exclusive license; Sagimet holds rights everywhere else. The 52-week data extend a 12-week Phase 3 readout in which, the company said, denifanstat met all primary and secondary endpoints across 480 randomized patients.

The comparable the company itself supplies is that earlier 12-week period. The extension enrolled 240 of those patients, 116 previously on denifanstat and 124 previously on placebo, for up to 40 further weeks and up to 52 weeks of total exposure for the continuous arm. Improvements continued past week 12 rather than plateauing.

The catalyst chain runs from China to the United States. Sagimet said patient screening for its own U.S. Phase 3 trial, AURORA, is expected to begin in October 2026, with first enrollment shortly after. The Chinese extension is therefore the long-term safety and durability evidence the company is carrying into a U.S. registration program.

The macro backdrop is secondary here. This is a single-asset clinical catalyst for a clinical-stage biopharmaceutical company, and the report gives no rate, index or sector-level data that bears on the readout.

What changed is timing. Sagimet now has 52 weeks of exposure data at the 50 mg dose it intends to take forward, and it has a crossover cohort that lets it compare patients who started denifanstat late against those who started at randomization.

Data — what the numbers show

Treatment success was defined as at least a two-point reduction from baseline in the Investigator's Global Assessment with a score of 0 (clear) or 1 (almost clear), measured against the ASC40-303 baseline.

Endpoint	Denifanstat/Denifanstat (n=116)	Placebo/Denifanstat (n=124)	Total (n=240)
Treatment success	57.8%	55.6%	56.7%
Total lesion change	-73.0%	-70.7%	-71.8%
Inflammatory lesion change	-78.1%	-75.8%	-76.9%
Non-inflammatory lesion change	-68.3%	-65.5%	-66.9%

The company noted that total and inflammatory lesion counts fell roughly 75% and 80% respectively for patients completing the extension. Baseline characteristics were consistent across arms: mean age 22.5 and 22.3 years, mean total lesion count 102.8 and 103.2, and inflammatory counts of 42.0 and 43.5. The original 480-patient trial skewed moderate, with 85.8% at IGA 3 and 14.2% at IGA 4.

On safety, the company said denifanstat was generally well-tolerated through up to 52 weeks, with no permanent discontinuations due to adverse events and no drug-related serious adverse events among treated patients. Only two treatment-related event categories exceeded 5% incidence: dry skin at 7.1% and dry eye at 5.9%.

Analysis — what it means for markets and sectors

Acne is a chronic-management market rather than a cure market, which is the commercial argument the company is making. Sagimet cites roughly 50 million Americans affected annually, more than 5 million seeking medical treatment each year, and about 10 million with moderate to severe disease. It also said denifanstat, if approved, would be the first oral acne treatment with a novel mechanism of action approved in more than forty years.

The crossover result is the clinically interesting one. Patients who spent 12 weeks on placebo and then 40 weeks on denifanstat reached 55.6% success against 57.8% for continuous treatment, a gap of 2.2 percentage points. That convergence supports the view that the drug's effect is exposure-driven rather than dependent on early randomization.

The limitation is structural. These are open-label extension results from a trial run in China by a partner, without a placebo comparator beyond week 12, and they cannot substitute for the randomized U.S. data AURORA is designed to produce. The company also did not disclose the cost, pricing or reimbursement assumptions behind the commercial opportunity it describes.

Positioning follows the catalyst calendar. SGMT is a clinical-stage name whose equity story rests on AURORA execution, so flow tends to concentrate around trial-start announcements, enrollment updates and any subsequent readout. Sector peers in dermatology and oral-systemic acne compete for the same moderate-to-severe patients.

Outlook — what to watch next

The first catalyst is AURORA screening, which the company expects to begin in October 2026, with first patient enrollment expected shortly after. The trial is intended to enroll approximately 800 U.S. patients aged 12 and older, including 450 adolescents aged 12 to 17, randomized 2:1 to denifanstat 50 mg or placebo once daily for 12 weeks.

The second is the design detail that matters for approvability: three co-primary endpoints at week 12 covering treatment success, absolute change in inflammatory lesions and absolute change in non-inflammatory lesions. A subset of roughly 530 completers will be eligible for a 40-week open-label extension.

The third is disclosure. The report gives no timeline for AURORA topline data and no regulatory submission dates for either territory. The company also said it will host a virtual key opinion leader event with Julie Harper, MD, on 30 September 2026 at 1 PM ET to review the 52-week data and the AURORA plan.

Frequently Asked Questions

What does the 52-week denifanstat data mean for retail investors in SGMT?

It extends the evidence base rather than changing it. The company now has safety data through up to 52 weeks of exposure and efficacy that kept improving past week 12, which is the package it carries into the U.S. AURORA trial. The report gives no revenue, pricing or approval timeline, so the readout is a development milestone, not a commercial one.

Why did patients who crossed over from placebo catch up to the denifanstat arm?

Sagimet's crossover cohort spent 12 weeks on placebo and then 40 weeks on denifanstat, reaching 55.6% treatment success versus 57.8% for continuous treatment. The company's chief medical officer, Andreas Grauer, said patients who crossed over achieved success rates similar to those treated from the start, which points to cumulative exposure rather than early-randomization advantage.

What happens next for the AURORA Phase 3 trial?

Sagimet said patient screening is expected to begin in October 2026, with first enrollment expected shortly after. AURORA targets roughly 800 U.S. patients aged 12 and older, including 450 adolescents, randomized 2:1 to denifanstat 50 mg or placebo for 12 weeks, with three co-primary endpoints. The report gives no date for topline results.

Bottom Line

Sagimet now has 52 weeks of denifanstat data and an October 2026 U.S. screening start, making AURORA execution the whole equity story.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.